PMC:7148425 / 1891-2056 JSONTXT

{"project":"2_test","denotations":[{"id":"32300370-32113509-46535320","span":{"begin":108,"end":109},"obj":"32113509"},{"id":"T12898","span":{"begin":108,"end":109},"obj":"32113509"}],"text":"y directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":35,"end":40},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T24","span":{"begin":49,"end":55},"obj":"NCBITaxon:10239"},{"id":"T57286","span":{"begin":35,"end":40},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T55368","span":{"begin":49,"end":55},"obj":"NCBITaxon:10239"}],"text":"y directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T11","span":{"begin":137,"end":138},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"y directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":35,"end":40},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"y directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes"}